When Rachel Pegram’s adult sons were younger, she often missed their soccer games and other school functions because of her generalized myasthenia gravis (gMG), a rare autoimmune disease that causes ...

Amid its push to switch patients from blockbuster to Soliris to follow-up drug Ultomiris, rare disease drugmaker Alexion has seen "unprecedented success" despite an activist investor's push for change ...

Dec 21 () - The U.S. Food and Drug Administration approved on Friday Alexion Pharmaceuticals Inc's rare blood disorder drug Ultomiris, an early backing that also solidifies the company's dominant ...

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2020 ...

Alexion’s decision to exercise its option, along with our other new collaborations in different therapeutic areas, underscores the growing recognition of the significant potential for RNAi therapies ...

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the launch of the Alexion Charitable Foundation to provide further support for the rare disease community and for local communities which ...

As federal authorities scrutinize relationships between drug makers and patient charities, Alexion Pharmaceuticals (ALXN) is the latest company to agree to settle allegations that donations amounted ...

Employees around the globe spark social media conversations to encourage dialogue about the rare disease patient journey BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) is ...

Alexion Pharmaceuticals said Wednesday it is buying Sweden’s Wilson Therapeutics for $855 million to expand its pipeline of drugs to treat rare diseases, as the pace of deal-making in the biotech ...

Alexion Pharmaceuticals (NASDAQ:ALXN) stock hasn’t moved much this year. But that’s not new. Despite growing its EBITDA per share by nearly 100% since 2018, the company’s stock has increased less than ...

AstraZeneca on Saturday announced it was acquiring Alexion Pharmaceuticals for $39 billion, a deal aimed at boosting AstraZeneca's immunology and rare-disease research, combining the companies' ...

TORONTO, ON - DECEMBER 2 - Toni Vernon poses at her Toronto home, December 2, 2014. Vernon has a rare blood disease called aHUS and must undergo dialysis three times a week. She needs access to ...